EMQN CIC to formally CPD accredit participation of EQA Assessors in 2023

EMQN CIC becomes an accredited provider of Continuing Professional Development (CPD) via CPD UK, and moves to formally accredit the participation of its volunteers / experts in the 2023 EQA assessment process

PRESS RELEASE: Manchester, United Kingdom, 16th September 2022 – EMQN CIC announced today that from 2023, EQA assessment meetings will be formally CPD accredited.

After successfully achieving CPD accreditation status via CPD UK, EMQN CIC will continue in 2023 (and beyond) to focus on formally recognising the educational achievements of its community of volunteer expert EQA assessment team members.

As an organisation rooted in quality, EMQN CIC understands the importance of continuing education and the expectation that its volunteers (clinical laboratory scientists, clinicians, and academics) maintain their CPD. We hope, that by formally recognising and accrediting the work our experts undertake, we are investing in an independent assessment of our educational activities to ensure we continue to deliver activities of high scientific value that promote applied learning.  

We are certain that CPD accreditation will add value to being a volunteer with EMQN CIC and fulfill the individual needs of the experts who support us, whilst simultaneously ensuring a structured and identifiable approach to learning.  

We are therefore calling on our community of members to become more involved with EMQN CIC by taking on a rewarding role as an EQA scheme assessment team member. You do not have to be an international expert to join us; we are looking for individuals with appropriate experience of clinical diagnostics and reporting. In addition to formalised CPD hours, see why becoming an EQA Assessor can benefit you (and your laboratory) by applying to join us here. 

– Ends –


EMQN CIC is a leading authority in quality assurance, committed to helping ensure clinical diagnostic genomics laboratory test results are accurate, reliable, and comparable – wherever they are produced. The organization was established in 1998 after a successful pilot trial of a Huntington disease EQA scheme the previous year. From January 1999 to March 2002, the network was supported by a grant from the European Commission under the Standards Measurement and Testing Programme (contract number SMT4-CT98-7515). Since April 2002, it has been supported by subscriptions from EQA scheme participants. In June 2021 EMQN was spun out of the UK public health service (NHS) as a Community Interest Company (CIC). The new company, EMQN CIC, currently offers 92 different EQA schemes across 7 different genomics themes including Molecular Genetics, Molecular Pathology, Pharmacogenetics, Pre and Postnatal testing (including non-invasive testing), Sequencing technologies (Sanger, NGS), Virology, and bespoke Interlaboratory Comparisons. For more information, please visit our website 

EMQN CIC is limited by guarantee and registered in England and Wales (Companies House Registration: 12020789). Our registered address is EMQN CIC, Unit 4, Enterprise House, Pencroft Way, Manchester Science Park, Manchester, M15 6SE, United Kingdom.